江苏省药品生产企业药物警戒工作现状抽样调查研究

doi:10.19803/j.1672-8629.2021.02.07

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (2): 133-137.
DOI: 10.19803/j.1672-8629.2021.02.07

江苏省药品生产企业药物警戒工作现状抽样调查研究

沈梦秋¹, 李明¹, 王佳域¹, 甘戈¹, 柳鹏程², 孙骏^1,*

¹江苏省药品不良反应监测中心,江苏南京 210002;
²中国药科大学,江苏南京 210000

收稿日期:2020-03-30 修回日期:2021-02-26 出版日期:2021-02-15 发布日期:2021-02-26
通讯作者: ^*孙骏,女,博士,主任药师,药品不良反应监测与评价。E-mail：18186210619@163.com
作者简介:沈梦秋,女,硕士,主管药师,药品不良反应监测与评价。

Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province

SHEN Mengqiu¹, LI Ming¹, WANG Jiayu¹, GAN Ge¹, LIU Pengcheng², SUN Jun^1,*

¹Jiangsu Adverse Drug Reaction Monitoring Center, Nanjing Jiangsu 210002, China;
²China Pharmaceutical University, Nanjing Jiangsu 210000, China

Received:2020-03-30 Revised:2021-02-26 Online:2021-02-15 Published:2021-02-26

摘要/Abstract

摘要： 目的本文立足于药品不良反应监测工作向药物警戒过渡的发展阶段,调查分析江苏省药品生产企业药物警戒工作的现状,为提升药品生产企业药物警戒工作能力提供依据与建议。方法采用问卷调查法,选取江苏省内药品生产企业代表,对其在药物警戒体系、药品安全性监测、药品风险管理等方面的工作现状进行调查,运用SPSS 22.0软件进行数据录入和统计。结果问卷调查覆盖各种类型药品生产企业共计108家,调查结果显示,大部分药品生产企业已初步建立药物警戒体系,在药品安全性监测方面的投入与成效日渐增加,但在药品风险管理方面相对薄弱。结论建议企业从提高重视程度、加强药物警戒体系建设、提升重点及薄弱环节工作有效性等方面加以完善,并建议监管部门及监测机构及时做好指南及培训相关配套。

关键词: 药物警戒, 持有人, 药品生产企业

Abstract: Objective To investigate the status quo of pharmacovigilance by drug manufacturers in Jiangsu Province, and to offer recommendations on how to improve pharmacovigilance by manufacturers amid the transition from monitoring of adverse drug reactions to pharmacovigilance. Methods After representatives of drug manufacturers in Jiangsu Province were selected, a questionnaire survey was conducted regarding the pharmacovigilance system, drug safety monitoring and risk management. SPSS 22.0 software was used for data entry and statistics. Results The survey covered 108 drug manufacturers of different types. The results indicated that most of the enterprises had established basic pharmacovigilance systems. Although the input into and effectiveness of ADR monitoring systems are increasing among those manufacturers, the level of risk management is relatively low. Conclusion It is recommended that manufacturers improve their awareness of drug safety, strengthen their pharmacovigilance systems, overcome their weaknesses, and that regulatory authorities and agencies provide related support in a timely manner.

Key words: pharmacovigilance, marketing authorization holder, drug manufacturers

中图分类号:

R969.3

沈梦秋, 李明, 王佳域, 甘戈, 柳鹏程, 孙骏. 江苏省药品生产企业药物警戒工作现状抽样调查研究[J]. 中国药物警戒, 2021, 18(2): 133-137.

SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun. Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.

参考文献

[1] Wang D, Peng LL, Liu CL.et al.Pharmacovigilance analysis and its difference from adverse drug reaction monitoring[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(3): 150-152, 157.
[2] Tian KR, Gao J, Miao J, et al. Analysis of adverse drug reaction monitoring and work system of pharmaceutical manufacturing enterprises in our province[J].Chinese Journal of Pharmacovigi- lance, 2014, 11(5): 285-287+290.
[3] Li JW, Liu ZR, Zeng YS, et al.Investigation and analysis of the status quo of adverse reaction monitoring in pharmaceutical manufacturers in guangdong[J]. China Pharmaceutical Affairs(中国药事), 2015, 29(5): 552-558.
[4] Zhang XM, Guo JD, Feng BL, et al.Investigation and Research on adverse drug reaction work of pharmaceutical manufacturers[J]. Medical Herald(医药导报), 2016, 35(8): 902-905.
[5] Shen MQ, Li M, Ma DH, et al.Analysis on the defects of the adverse drug reaction report and monitoring inspection in Jiangsu Province in 2016[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2017, 25(6): 553-556.
[6] Sang Y, Wu SF, Lu CF, et al.Problems and thinking of adverse drug reaction reports and monitoring of manufacturing enterprises from the perspective of inspection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 215-218.
[7] Xi XY, Li GF.Introduction to the pharmacovigilance regulatory system of the United States, the european union and Japan[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2010, 19(10): 587-591.
[8] Wang T, Wang D, Dong Y, et al.Analysis of American pharmacovigilance system and its enlightenment to my country[J]. Herald of Medicine, 2017, 36(4): 361-365.
[9] Tian F.Translation of the pharmacovigilance system for human pharmaceutical products in the european union[J]. Chinese Patent Medicine(中成药), 2012, 32(12): 2154-2157.
[10] Yang Y.Research on the implementation issues of the direct reporting adverse reaction system for drug marketing authorization holders[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(11): 649-653, 665.
[11] Wang D, Li QL, Dong D, et al.Investigation and research on the ability of directly reporting adverse reactions in pharmaceutical manufacturers[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(11): 654-661.
[12] Ren JT, Zheng WK, Zhang JH, et al.The important role of the manufacturer in the risk management of the drug after the market[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(2): 88-93.
[13] Sun Y.The origin, development and prospect of pharmacovigil- ance[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2010, 19(8): 454-461.
[14] Zhong LM.Discussion on the main responsibility of the drug marketing license holder in the life cycle of the drug[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(11): 666-669, 677.

[1]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[2]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[3]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[4]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[5]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[6]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[7]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[8]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[9]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.
[10]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[11]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[12]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[13]	叶培, 张鹤巍, 吕强, 叶小飞, 许金芳, 郭晓晶. 基于FAERS 数据库舒更葡糖逆转神经肌肉阻滞安全性研究[J]. 中国药物警戒, 2023, 20(3): 321-325.
[14]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[15]	雷超, 乔萌, 陈子佳, 张强, 谢雁鸣, 王志飞. 中成药说明书安全性信息项修订的探讨与思考[J]. 中国药物警戒, 2023, 20(12): 1396-1400.

江苏省药品生产企业药物警戒工作现状抽样调查研究

Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics